Investment Management Corp of Ontario Takes $279,000 Position in DaVita Inc. (NYSE:DVA)

Investment Management Corp of Ontario bought a new position in shares of DaVita Inc. (NYSE:DVA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,704 shares of the company’s stock, valued at approximately $279,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Atom Investors LP purchased a new stake in shares of DaVita during the 3rd quarter worth approximately $4,094,000. Assenagon Asset Management S.A. raised its stake in DaVita by 29.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock worth $6,942,000 after acquiring an additional 11,454 shares in the last quarter. Quest Partners LLC purchased a new stake in DaVita in the third quarter valued at $669,000. MBB Public Markets I LLC acquired a new position in DaVita in the second quarter valued at $582,000. Finally, Centiva Capital LP grew its holdings in shares of DaVita by 61.2% during the third quarter. Centiva Capital LP now owns 15,207 shares of the company’s stock worth $2,493,000 after purchasing an additional 5,776 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on DVA. Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial increased their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $161.80.

DaVita Stock Performance

Shares of DVA stock opened at $160.25 on Monday. DaVita Inc. has a 52-week low of $103.40 and a 52-week high of $169.51. The stock’s 50-day moving average price is $158.58 and its 200 day moving average price is $150.34. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The stock has a market capitalization of $13.14 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 0.92 and a beta of 0.90.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter last year, the company earned $2.85 EPS. DaVita’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, equities research analysts forecast that DaVita Inc. will post 9.71 EPS for the current year.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This represents a 5.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.